Vyvanse (lisdexamfetamine) is a prescription stimulant prescribed for ADHD and, uniquely among amphetamines, for moderate-to-severe binge eating disorder. It works by raising levels of dopamine and noradrenaline, the two neurotransmitters that drive focus, motivation, and arousal. It does this in two ways: it reverses the transporters that normally clear these neurotransmitters from the synapse, causing them to release into the synapse rather than reabsorb out of it, and it displaces the neurotransmitters stored inside vesicles within the neuron, increasing the amount available for release. The result is sustained, elevated dopamine and noradrenaline signalling in the regions of the brain responsible for attention and executive control.
The active drug is dextroamphetamine, the same molecule that makes up most of Adderall. What's different about Vyvanse is how it gets there. The molecule you swallow is inactive, a piece of d-amphetamine chemically tethered to the amino acid lysine, and it can't do anything until enzymes inside your red blood cells slowly snip the lysine off and release the active drug into circulation. That single mechanism change is what most people are actually choosing when they pick Vyvanse over Adderall: a smoother, slower rise, a longer-lasting plateau (12-14 hours), a less intense come-down, and a meaningfully lower abuse potential because the rate of activation is fixed by your own biology rather than the dose or the route.
It's a real amphetamine with real amphetamine costs (sleep disruption, appetite suppression, cardiovascular load, tolerance, dependence), and the prodrug doesn't make those go away. What it does is replace the fast on/fast off curve of immediate-release amphetamines with a flatter one, which most people experience as steadier, more functional, and less euphoric. If you want "on the medication" to feel like "a slightly better version of normal" rather than "a different state", that's the practical case for Vyvanse.
Deep-dive
Lisdexamfetamine is d-amphetamine covalently bonded to the amino acid l-lysine. After oral dosing, it's absorbed intact through the small intestine (probably via the peptide transporter PEPT1), enters the bloodstream still as the inactive prodrug, and is then hydrolysed by aminopeptidase activity in the cytosol of red blood cells, releasing d-amphetamine and l-lysine into circulation. RBC hydrolysis is the rate-limiting step. This matters more than it sounds: it means the speed at which active drug appears in your blood is set by enzyme kinetics, not by GI absorption, not by tablet dissolution, not by the route of administration. Crush it, snort it, dissolve it and inject it, the active drug still has to wait for your red blood cells to process it.
Once d-amphetamine reaches the brain, the rest is identical to any other amphetamine. It enters dopamine and noradrenaline neurons via their reuptake transporters, reverses those transporters so they pump neurotransmitter out into the synapse, enters synaptic vesicles via VMAT2 and displaces stored neurotransmitter into the cytoplasm, and weakly inhibits monoamine oxidase. The combined effect is sustained elevation of extracellular dopamine and noradrenaline in the prefrontal cortex and striatum.
Pharmacokinetic profile. Plasma d-amphetamine peaks 3-5 hours after oral lisdexamfetamine, compared to roughly 3 hours for immediate-release d-amphetamine and 7 hours for Adderall XR. The d-amphetamine half-life is about 9-11 hours, similar across formulations, but the slower rise and the lower peak give Vyvanse a flatter curve. The therapeutic effect in adults extends to at least 14 hours post-dose, longer than any other long-acting amphetamine formulation. Inter- and intra-patient variability is also lower than with other long-acting stimulants, which translates into a more predictable daily experience.
Dose equivalence. Vyvanse is dosed by the weight of the whole prodrug molecule, not by the d-amphetamine you actually receive. Roughly: 30 mg lisdexamfetamine yields about 8.9 mg d-amphetamine, 50 mg yields about 14.8 mg, and 70 mg (the maximum approved dose) yields about 20.8 mg. By comparison, Adderall is roughly 75% d-amphetamine and 25% l-amphetamine, so 30 mg Adderall delivers about 22.5 mg of d-amphetamine-equivalent activity. The widely used clinical conversion is that 70 mg Vyvanse is roughly equivalent to 30 mg Adderall XR, though individual response varies and many people switching find the optimal dose is one step different from the calculated equivalent.
ADHD efficacy. The evidence base is large and consistent. Lisdexamfetamine produces clinically meaningful improvements in ADHD symptoms across paediatric, adolescent, and adult populations, with effect sizes comparable to other amphetamines. Head-to-head trials against Adderall XR generally show similar efficacy with a longer functional duration of effect and, in some studies, a smoother subjective experience. The mechanistic story is the same as Adderall: ADHD brains have weaker tonic dopamine and noradrenaline tone in the prefrontal cortex, and stimulants restore signalling toward a typical range.
Binge eating disorder. This is where Vyvanse is genuinely distinctive. It's the only FDA-approved medication for binge eating disorder, based on two large Phase 3 trials at 50 or 70 mg daily showing significant reductions in binge eating days per week versus placebo over 12 weeks. A subsequent maintenance trial found continued lisdexamfetamine treatment reduced relapse risk roughly elevenfold compared with placebo over six months (3.7% vs 32.1% relapse). A 2025 network meta-analysis covering 12 trials found lisdexamfetamine comparable to topiramate for reducing binge frequency, with weight loss around 4.6 kg on average. The mechanism is thought to involve dopamine and noradrenaline modulation of impulse control and reward signalling around food, not just appetite suppression.
Cognitive enhancement in healthy people. Same caveat as Adderall. The cultural narrative is much stronger than the evidence. Healthy non-ADHD adults given stimulants reliably report feeling sharper, but objective performance gains in working memory, executive function, and attention are small and inconsistent, with frequent decrements in creativity and cognitive flexibility. The subjective feeling and the objective performance often dissociate.
Abuse liability. The PK profile is the key feature here. Because RBC hydrolysis is the rate-limiting step, supratherapeutic doses do not produce proportionally larger peaks, and intranasal or intravenous administration produces a curve very similar to oral. Subjective drug-liking effects are reduced compared to equimolar oral d-amphetamine in some studies. That said, comparable oral exposure produces comparable oral abuse liability, the prodrug doesn't make the drug non-addictive, it just blunts the routes of administration favoured by recreational users. Schedule II status reflects this: real abuse potential, but lower than immediate-release amphetamines.
Tolerance and adaptation. A systematic review of stimulant users shows reduced D2/D3 receptor availability, reduced dopamine release, and reduced dopamine transporter levels with chronic exposure. Some of this likely predates use, but longitudinal evidence shows further reductions develop on chronic dosing. The smoother PK of Vyvanse may slow this somewhat compared to immediate-release stimulants, but it doesn't eliminate it. Functionally this looks like: the original effect fades, the dose creeps up, motivation off-drug feels blunter, and the gap between therapeutic and uncomfortable narrows.
Cardiovascular load. Modest in the short term. Adult meta-analyses of amphetamines consistently show systolic BP rises of about 2 mmHg and heart rate increases of about 5 bpm. The slower, flatter PK of Vyvanse may be slightly easier on the heart at peak than immediate-release amphetamine at peak, but the integrated daily exposure is similar at equivalent doses. People with pre-existing structural heart disease, uncontrolled hypertension, or a family history of sudden cardiac death need specialist input before starting.
Women. Women metabolise amphetamines somewhat differently from men. At unadjusted doses, plasma amphetamine concentrations run 20-30% higher in women than men, mostly explained by body mass and composition rather than a female-specific metabolic pathway. CYP2D6 genotype affects d-amphetamine clearance, and slow metabolisers (more common in some populations) can run substantially higher plasma levels at a standard mg dose.
The cycle effect is the more underappreciated lever. Oestrogen upregulates dopamine synthesis, release, and receptor sensitivity, so stimulant sensitivity is meaningfully higher in the follicular phase and lower in the luteal phase. A study by Justice and colleagues on dextroamphetamine in 16 healthy women found subjective drug effects were significantly stronger during the follicular phase. A pilot study in women on amphetamine salts for ADHD found ADHD symptoms were most severe during menstruation and mildest in the mid-follicular phase, tracking with oestrogen. A 2023 paper from a Dutch ADHD clinic showed that women who increased their stimulant dose in the premenstrual week saw improvement in both ADHD and mood symptoms. None of this is in the FDA label, and most prescribers don't ask. If you menstruate and find your Vyvanse "stops working" the week before your period, this is probably why, and a small late-luteal dose bump is worth discussing with your prescriber.
Pregnancy is generally avoided. Amphetamines cross the placenta and observational data link in-utero exposure to lower birth weight and possible developmental effects. Continuing is occasionally justified for severe ADHD when the risk of untreated illness outweighs exposure, but only under specialist care.
Dosage:
- Starting dose: 30 mg once daily in the morning, the standard FDA-approved starting dose for both ADHD and binge eating disorder
- Titration: Adjust by 10-20 mg at weekly intervals based on response
- Effective range: Most adults stabilise between 30-70 mg/day. For ADHD, 50-70 mg is the typical effective dose. For binge eating disorder, the trials that established efficacy used 50 or 70 mg
- Maximum: 70 mg/day. Above this, the FDA-approved label doesn't authorise dosing, and pharmacokinetics don't reward it the way they reward titration in IR formulations
- Take it in the morning, ideally before 9am. Vyvanse's effect lasts 12-14 hours, so afternoon dosing will damage your sleep that night and the next. The slow on-ramp means it doesn't feel "too early", but the tail is long
- Take with or without food, doesn't matter much. Unlike Adderall, Vyvanse is not sensitive to gastric pH or acidic foods, the activation happens in the bloodstream not the gut. Orange juice, vitamin C, and citrus don't blunt it the way they blunt Adderall
- Eat anyway. Appetite suppression is the rule. Set fixed mealtimes (breakfast before you dose, lunch on a clock, dinner whether or not you're hungry) and eat on schedule. Skipping meals on Vyvanse is the fastest route to fatigue, malnutrition, and an ugly comedown
- Hydrate aggressively. Stimulants suppress thirst signalling and increase fluid loss
- The capsule can be opened. If you can't swallow capsules, the contents can be dissolved in water, yoghurt, or orange juice and consumed immediately. The full dose is bioequivalent to the capsule
- Cycle awareness for women. If you menstruate and notice your dose feels weak the week before your period, the late luteal drop in oestrogen is a known mechanism. Some clinicians adjust dose upward by a small amount in that window. Discuss with your prescriber rather than self-adjusting
- Converting from Adderall: As a rough guide, 70 mg Vyvanse ≈ 30 mg Adderall XR ≈ 20 mg Adderall IR BID. Individual response varies. Most people switching find their optimal Vyvanse dose is one step (10-20 mg) different from the simple equivalence
- Drug holidays. Some take weekends off to reduce tolerance and let sleep, appetite, and mood reset. Useful for some, destabilising for others. Vyvanse's smoother profile makes weekend skips less jarring than skipping IR amphetamine, but discuss with your prescriber
- Tolerance is real. If you find yourself needing more for the same effect, the answer is rarely a higher dose. It's usually a tolerance break, a switch in formulation or medication, or a hard look at sleep, food, and stress
Here's what you can expect:
The onset is gradual. You probably won't feel the dose hit. Effects start to build around 60-90 minutes in, peak somewhere between 3 and 5 hours, and gently taper through the rest of the day. The first few days on a new dose can feel underwhelming because Vyvanse doesn't deliver the "oh, it's working" moment that Adderall IR does. By day three or four most people have a clearer read on the effective dose.
If you have ADHD, the experience is usually described as the background noise quieting down. Tasks that felt impossible become approachable, working memory holds, and the impulsivity loop loosens. Compared to Adderall, the experience is steadier and less obviously "on". A lot of people who switch to Vyvanse report that they stopped noticing the medication after a few weeks, which is generally a feature.
If you don't have ADHD, expect a milder version of classic stimulant arousal: focused, talkative, suppressed appetite, less need for sleep. The euphoric/recreational quality is meaningfully reduced compared to IR amphetamines, which is exactly the point of the prodrug design.
For everyone, expect a comedown, but a softer one than with IR formulations. As d-amphetamine clears in the evening, irritability, fatigue, and low mood can still hit, just over a longer window. Sleep that night will probably be lighter and shorter than usual. The cumulative sleep debt is one of the major reasons people end up feeling worse on long-term stimulants than they expected, and it sneaks up because the daytime experience stays smooth.
With chronic use, the magic-pill quality fades. The dose that used to feel transformative starts to feel like baseline, and stopping it produces a noticeable functional drop. This isn't necessarily addiction in the clinical sense, but it is a kind of dependence that's worth being honest about.
Side effects & risks:
- Cardiovascular: Elevated heart rate (typically 5-10 bpm) and blood pressure (typically 2-5 mmHg systolic) are near-universal. People with structural heart disease, uncontrolled hypertension, hyperthyroidism, or a family history of sudden cardiac death should not take Vyvanse without specialist clearance. Chest pain, palpitations, or fainting on the medication require immediate evaluation
- Sleep: Insomnia, delayed sleep onset, and reduced sleep quality. The 12-14 hour duration of action means even a morning dose can affect that night's sleep. Don't dose past mid-morning
- Appetite and weight: Significant appetite suppression and weight loss are expected. In adults this is usually manageable with scheduled meals; in growing children and adolescents it can affect growth trajectory and requires monitoring
- Dry mouth, headache, GI upset, sweating, dizziness: Common, usually tolerable, often improve over the first 1-2 weeks
- Anxiety, agitation, irritability: Common, dose-dependent. Can manifest as a tightly wound feeling, a snappy mood, or full anxiety. Often worse on the late tail or comedown
- Mood and psychiatric: Stimulants can unmask or worsen anxiety disorders, bipolar disorder, and psychosis. New paranoid thinking, grandiosity, or hallucinations require stopping the medication and speaking to a doctor. People with a family history of psychotic illness should be cautious
- Sexual: Variable. Some report increased libido, others report erectile dysfunction or anorgasmia. Often dose-dependent
- Menstrual: Changes in cycle length or bleeding are occasionally reported. Painful cramps appear on the label
- Tolerance and dependence: Real, dose-dependent. Stimulant use disorder is a recognised condition. Risk scales with dose, duration, and personal or family history of substance use disorder. The prodrug design lowers abuse liability via routes-of-administration but does not eliminate dependence at therapeutic oral dosing
- Withdrawal: Stopping abruptly after sustained use produces fatigue, low mood, increased appetite, vivid dreams, and difficulty concentrating, lasting days to weeks. Worse after high-dose long-term use. Tapering is usually preferable
- Drug interactions: MAOIs are an absolute contraindication, the combination can cause hypertensive crisis. SSRIs and SNRIs can interact (serotonin syndrome risk, especially at higher doses or in combination with other serotonergic drugs). Other stimulants and decongestants compound cardiovascular load. Unlike Adderall, acidifying agents (vitamin C, fruit juice) do not significantly reduce Vyvanse absorption, since activation happens in the blood
- Pregnancy and breastfeeding: Generally avoided. Crosses the placenta, present in breast milk. Discuss with a specialist if you have severe ADHD or binge eating disorder and become pregnant
- Schedule II controlled substance in the US and similarly restricted elsewhere. Diversion, sharing, and possession without a prescription carry serious legal consequences
Blood markers
Resting heart rate and blood pressure, baseline before starting and rechecked at 1 month, 3 months, then twice yearly. This is the single most important monitoring step. Sustained increases above baseline warrant a dose review.
ECG, baseline if you have any cardiac history, family history of sudden cardiac death, structural heart concerns, or are over 40 starting stimulants for the first time. Not routinely required in young healthy adults but the threshold to get one is low.
TSH, free T4, free T3, baseline. Hyperthyroidism mimics stimulant side effects and is a contraindication. Worth knowing your numbers before you can't tell which is which.
CBC and comprehensive metabolic panel (kidney and liver function, electrolytes), baseline and annually. Stimulants don't typically damage these but you want a reference, especially if appetite suppression is significant.
Weight, tracked. Both for safety (excessive loss) and dosing (your dose is partly based on body mass, particularly for women).
Sleep, tracked subjectively or with a wearable. Sleep degradation is the most common silent cost of long-term stimulant use and the easiest to ignore. Vyvanse's long tail makes this especially worth watching.
Most people on a stable Vyvanse dose under specialist care don't need anything beyond annual vitals, BP, and a check-in. The people who actually need more workup are anyone over 40, anyone with cardiovascular risk factors, women noticing strong cycle-related variability, and anyone whose dose has been climbing.
Prescription-only Schedule II controlled substance in the US and a similarly restricted prescription medication in most other countries.
Made with Bullet